254 related articles for article (PubMed ID: 36281115)
1. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis.
Temmoku J; Migita K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Watanabe H; Miyata M
Medicine (Baltimore); 2022 Oct; 101(42):e31161. PubMed ID: 36281115
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
[TBL] [Abstract][Full Text] [Related]
4. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
5. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Cho SK; Kim H; Song YJ; Kim HW; Nam E; Lee SS; Lee HS; Park SH; Lee YA; Park MC; Chang SH; Kim HA; Kwok SK; Kim HR; Kim HS; Yoon BY; Uhm WS; Kim YG; Kim JH; Lee J; Choi J; Sung YK
Korean J Intern Med; 2023 Jul; 38(4):546-556. PubMed ID: 37334513
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
[TBL] [Abstract][Full Text] [Related]
9. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
10. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
[TBL] [Abstract][Full Text] [Related]
12. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
[TBL] [Abstract][Full Text] [Related]
13. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
15. Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.
Kwon OC; Choi W; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Park MC; Kim YG
Adv Rheumatol; 2024 Apr; 64(1):26. PubMed ID: 38622706
[TBL] [Abstract][Full Text] [Related]
16. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
17. After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
Pombo-Suarez M; Sanchez-Piedra C; Gómez-Reino J; Lauper K; Mongin D; Iannone F; Pavelka K; Nordström DC; Inanc N; Codreanu C; Hyrich KL; Choquette D; Strangfeld A; Leeb BF; Rotar Z; Rodrigues A; Kristianslund EK; Kvien TK; Elkayam O; Lukina G; Bergstra SA; Finckh A; Courvoisier DS
Ann Rheum Dis; 2023 Feb; 82(2):175-181. PubMed ID: 36100351
[TBL] [Abstract][Full Text] [Related]
18. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
Sonomoto K; Tanaka Y
Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
[TBL] [Abstract][Full Text] [Related]
19. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
[TBL] [Abstract][Full Text] [Related]
20. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
